While many people are focused on the future of a potential Supreme Court nominee, the D.E.A. made a decision that will impact patients across the country.
Per MJ Biz Daily
The U.S. Drug Enforcement Administration has taken some cannabidiol out of the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval.
It’s a decision that immediately affects CBD producers but also signals the agency’s first admission that the plant has medical value.
The DEA announced Thursday that drugs including CBD with THC content below 0.1% are now considered Schedule 5 drugs, as long as they have been approved by the U.S. Food and Drug Administration.
Read more here
